Galectin Therapeutics Inc [GALT] stock is trading at $1.10, down -4.35%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The GALT shares have gain 5.77% over the last week, with a monthly amount drifted -61.20%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Galectin Therapeutics Inc [NASDAQ: GALT] stock has seen the most recent analyst activity on August 13, 2020, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $12 from $9. Previously, B. Riley FBR started tracking the stock with Buy rating on February 13, 2019, and set its price target to $11. On December 07, 2017, H.C. Wainwright reiterated its Buy rating and revised its price target to $10 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $6 on November 28, 2017. ROTH Capital initiated its recommendation with a Buy. H.C. Wainwright upgraded its rating to Buy for this stock on March 30, 2017, but kept the price target unchanged to $3.50. In a note dated October 03, 2016, FBR & Co. downgraded an Mkt Perform rating on this stock and revised its target price from $12 to $2.
Galectin Therapeutics Inc [GALT] stock has fluctuated between $0.73 and $4.27 over the past year. Galectin Therapeutics Inc [NASDAQ: GALT] shares were valued at $1.10 at the most recent close of the market.
Analyzing the GALT fundamentals
Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -494.57%, Pretax Profit Margin comes in at -563.46%, and Net Profit Margin reading is -563.46%. To continue investigating profitability, this company’s Return on Assets is posted at -1.56, Equity is 0.59 and Total Capital is -10.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9467 points at the first support level, and at 0.7933 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2467, and for the 2nd resistance point, it is at 1.3933.
Ratios To Look Out For
For context, Galectin Therapeutics Inc’s Current Ratio is 1.13. As well, the Quick Ratio is 1.13, while the Cash Ratio is 1.07.
Transactions by insiders
Recent insider trading involved Jamil Khurram, Chief Medical Officer, that happened on Dec 23 ’24 when 13654.0 shares were sold. President and CEO, LEWIS JOEL completed a deal on Dec 23 ’24 to sell 56000.0 shares. Meanwhile, Chief Financial Officer CALLICUTT JACK W sold 40000.0 shares on Dec 23 ’24.
